

### **FORWARD-LOOKING STATEMENTS**


Except for historical information, certain matters discussed in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to all projections and anticipated levels of future performance. Forward-looking statements involve risks, uncertainties and other factors that may cause our actual results to differ materially from those discussed herein. Any number of factors could cause actual results to differ materially from projections or forward-looking statements, including without limitation, changes to global economic, social and political conditions, spending patterns of government agencies, competitive pressures, the impact of acquisitions and related integration activities, logistical challenges related to disruptions and delays, product liability claims, the success of new product introductions, currency exchange rate fluctuations and the risks of doing business in the markets in which we operate, including foreign countries. More information on potential factors that could affect the Company's financial results are more fully described from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this presentation are based upon information available to the Company as of the date of this presentation, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this presentation.



# **TODAY'S PRESENTERS**




Chief Executive Officer and Chairman of the Board



**BRAD WILLIAMS** 





BLAINE BROWERS
Chief Financial Officer



# **AGENDA**

- Q2 Highlights
- Business Overview
- Financial Summary
- Full Year Outlook
- Conclusion and Q&A





# CONTINUED EXECUTION IN Q2

Cadre continues to deliver on strategic objectives, generating record quarterly adj. EBITDA and achieving significant margin expansion

### Commentary:

Pricing Growth: 

Exceeded target

Q2 Mix: Favorable mix in duty gear, armor and Distribution, offset by lower EOD volume

Orders Backlog: 

✓ Increased by \$15.3 million in 2023; driven by higher demand for armor, offset by a decline in

Distribution backlog

Healthy M&A Funnel: 

✓ Continue to actively evaluate pipeline of opportunities

Returned Capital to Shareholders: 

Declared eighth consecutive quarterly dividend of \$0.08



# MACRO TAILWINDS SUPPORT LONG TERM SUSTAINABLE GROWTH OPPORTUNITY



Police protection expenditures have continued to trend upward even during previous financial and industrial recessions

Major US cities continue to increase police budgets

The American Rescue Plan provides \$350 billion to hire more police

Two-thirds of all NATO countries spend less than 2% of GDP targets on defense and security

Amidst current geopolitical turmoil, European leaders have advocated for significant increases in defense budgets



### **LATEST MARKET TRENDS**

North American Law Enforcement

 Spend per officer increasing but police departments still struggling to fill open positions

Geopolitical Landscape

Given increasing scale of unexploded ordinance in Ukraine, expectation is that the demining process will take decades, which represents a longer cycle of opportunity for Cadre

Supply Chain/ Labor

- Improving supply chain with limited pockets of extended lead times
- Managing labor force for long-term

Consumer

 Demand for Cadre's products is strong but monitoring broader macro consumer demand environment

New Products/ Innovation

 Continue to hear positive feedback on newly introduced HyperX tactical armor platform, Xpertfit 3D body sizing app and SafariVault line of holsters



# **CADRE'S KEY M&A CRITERIA**

#### **Business**


- ☑ Cost structure where material > labor
- High cost of substitution

### **Financial**

- ☑ Recurring revenue profile
- Attractive ROIC

#### **Market**

- ☑ Niche market
- ☑ No large-cap competition
- ☑ Resiliency through market cycles



# **SECOND QUARTER 2023 FINANCIAL PERFORMANCE**



	Q2 2023	Q1 2023	Q2 2022
NET SALES	\$121.1M	\$111.7M	\$118.2M
GROSS MARGIN	41.9%	41.7%	36.6%
NET INCOME	\$11.0M / \$0.29 per diluted share	\$7.0M / \$0.19 per diluted share	\$4.4M / \$0.12 per diluted share
ADJUSTED EBITDA <sup>1</sup>	\$22.8M	\$18.6M	\$18.4M
ADJUSTED EBITDA MARGIN <sup>1</sup>	18.8%	16.6%	15.6%

- Increased quarterly net sales, adjusted EBITDA, net income, gross profit and adjusted EBITDA margin sequentially and yearover-year
- Achieved pricing growth that exceeded target and grew orders backlog YTD




### **NET SALES AND ADJUSTED EBITDA**


Current Period Net Sales and Adj. EBITDA

Full Year Guidance for Net Sales and Adj. EBITDA

### **NET SALES (\$MM)**



### ADJ. EBITDA<sup>1</sup>(\$MM)





# **Q2 2023 CAPITAL STRUCTURE**

	June 30, 2023	
(in thousands)		
Cash and cash equivalents	\$ 55,782	
Debt:		
Revolver	\$ _	
Current portion of long-term debt	10,022	
Long-term debt	134,089	
Capitalized discount/issuance costs	(1,377)	
Total debt, net	\$ 142,734	
Net debt (Total debt net of cash)	\$ 86,952	
Total debt / Adj. EBITDA <sup>(1)</sup>	1.7	
Net debt / Adj. EBITDA <sup>(1)</sup>	1.0	
Adj. EBITDA <sup>(1)</sup>	\$ 84,523	



# **UPDATED 2023 MANAGEMENT OUTLOOK**



**2023 GUIDANCE** 

**NET SALES** 

\$472M to \$484M

ADJ. EBITDA

\$80M to \$84M

**CAPITAL EXPENDITURES** 

\$8M to \$9M



# **CONCLUSION**





# **BALANCE SHEET**

### **UNAUDITED (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)**

	June 30, 2023	December 31, 2022
Assets		
Current assets		
Cash and cash equivalents	\$ 55,782	\$ 45,286
Accounts receivable, net of allowance for doubtful accounts of \$800 and \$924, respectively	57,361	64,557
Inventories	82,777	70,273
Prepaid expenses	10,009	10,091
Other current assets	6,406	6,811
Total current assets	212,335	197,018
Property and equipment, net of accumulated depreciation and amortization of \$47,046 and \$42,694, respectively	44,531	45,285
Operating lease assets	6,657	8,489
Deferred tax assets, net	2,351	2,255
Intangible assets, net	46,919	50,695
Goodwill	81,560	81,576
Other assets	5,566	6,634
Total assets	\$ 399,919	\$ 391,952
Liabilities, Mezzanine Equity and Shareholders' Equity		
Current liabilities		
Accounts payable	\$ 29,640	\$ 23,406
Accrued liabilities	34,480	38,720
Income tax payable	4,279	4,584
Liabilities held for sale	_	_
Current portion of long-term debt	10,022	12,211
Total current liabilities	78,421	78,921
Long-term debt	132,712	137,476
Long-term operating lease liabilities	3,211	4,965
Deferred tax liabilities	3,759	3,508
Other liabilities	1,314	1,192
Total liabilities	219,417	226,062
Mezzanine equity		
Preferred stock (\$0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022)	_	_
Shareholders' equity		
Common stock (\$0.0001 par value, 190,000,000 shares authorized, 37,586,031 and 37,332,271 shares issued and outstanding as of June 30, 2023 and December 31, 2022,		
respectively)	4	4
Additional paid-in capital	208,492	206,540
Accumulated other comprehensive income	2,746	2,087
Accumulated deficit	(30,740)	(42,741)
Total shareholders' equity	180,502	165,890
Total liabilities, mezzanine equity and shareholders' equity	\$ 399,919	\$ 391,952



# STATEMENT OF OPERATIONS

### **UNAUDITED (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)**

	Three Months E	Ended Ju	ıne 30,	Six Months Ended June 30,			
	2023		2022		2023	2022	
Net sales	\$ 121,087	\$	118,232	\$	232,835	\$	222,638
Cost of goods sold	70,340		75,011		135,470		139,228
Gross profit	50,747		43,221		97,365		83,410
Operating expenses							
Selling, general and administrative	34,051		32,749		69,301		86,699
Restructuring and transaction costs	693		1,203		693		1,802
Related party expense	115		1,112		263		1,234
Total operating expenses	34,859		35,064		70,257		89,735
Operating income (loss)	15,888		8,157		27,108		(6,325)
Other expense							
Interest expense	(1,013)		(1,439)		(2,654)		(2,929)
Other income (expense), net	346		(756)		710		(961)
Total other expense, net	(667)		(2,195)		(1,944)		(3,890)
Income (loss) before provision for income taxes	15,221		5,962		25,164		(10,215)
(Provision) benefit for income taxes	(4,229)		(1,517)		(7,170)		4,495
Net income (loss)	\$ 10,992	\$	4,445	\$	17,994	\$	(5,720)
Net income (loss) per share:							
Basic	\$ 0.29	\$	0.13	\$	0.48	\$	(0.16)
Diluted	\$ 0.29	\$	0.12	\$	0.48	\$	(0.16)
Weighted average shares outstanding:							
Basic	37,586,031		35,320,314		37,480,367		34,888,703
Diluted	37,850,708		35,688,620		37,758,998		34,888,703



# STATEMENT OF CASH FLOWS

### **UNAUDITED (IN THOUSANDS)**

ONAUDITED (IN THOUSANDS)		Six Months Ended June 30,						
	20	023	2022					
Cash Flows From Operating Activities:								
Net income (loss)	\$	17,994	\$ (5,720					
Adjustments to reconcile net income (loss) to net cash provided by operating activities:								
Depreciation and amortization		8,220	7,380					
Amortization of original issue discount and debt issue costs		374	367					
Amortization of inventory step-up		_	1,344					
Deferred income taxes		14	(4,594					
Stock-based compensation		4,852	26,327					
Gain on sale of fixed assets		(108)						
(Recoveries from) provision for losses on accounts receivable		(21)	240					
Foreign exchange (gain) loss		(776)	1,107					
Other		(325)						
Changes in operating assets and liabilities, net of impact of acquisitions:								
Accounts receivable		7,605	(3,243					
Inventories		(11,986)	(1,461					
Prepaid expenses and other assets		3,397	3,616					
Accounts payable and other liabilities		(971)	(345					
Net cash provided by operating activities		28,269	25,018					
Cash Flows From Investing Activities:								
Purchase of property and equipment		(2,404)	(2,473					
Proceeds from disposition of property and equipment		206						
Business acquisitions, net of cash acquired		_	(55,039					
Net cash used in investing activities		(2,198)	(57,512					

Continued on next slide



# **STATEMENT OF CASH FLOWS - CONTINUED**

### **UNAUDITED (IN THOUSANDS)**

	Year E	Year Ended June 30,			
	2023		2022		
Cash Flows From Financing Activities:					
Proceeds from revolving credit facilities	-	_	48,000		
Principal payments on revolving credit facilities	-	-	(48,000)		
Principal payments on term loans	(5,000	))	(5,009)		
Principal payments on insurance premium financing	(2,18)	9)	(2,853)		
Payment of capital leases	-	_	(22)		
Taxes paid in connection with employee stock transactions	(2,72	5)	(6,216)		
Proceeds from secondary offering, net of underwriter discounts	-	_	49,703		
Deferred offering costs	-	_	(2,715)		
Dividends distributed	(5,993	3)	(5,533)		
Net cash (used in) provided by financing activities	(15,90)	7)	27,355		
Effect of foreign exchange rates on cash and cash equivalents	333	2	144		
Change in cash and cash equivalents	10,496	3	(4,995)		
Cash and cash equivalents, beginning of period	45,286	3	33,857		
Cash and cash equivalents, end of period	\$ 55,783	2 \$	28,862		
Supplemental Disclosure of Cash Flows Information:					
Cash paid for income taxes, net	\$ 7,288	3 \$	241		
Cash paid for interest	\$ 4,859	\$	2,330		
Supplemental Disclosure of Non-Cash Investing and Financing Activities:					
Accruals and accounts payable for capital expenditures	\$ 129	\$	17		



## **NON-GAAP RECONCILIATION**

#### (IN THOUSANDS)

	Year ended Three Months  December 31, Ended March 31,		Three Months Ended				Six Months Ended					Last Twelve		
			r 31, Ended March 31,			June 30,			June 30,				Months	
	2	2022		2023		2023		2022		2023		2022	June	30, 2023
Net income (loss)	\$	5,820	\$	7,002	\$	10,992	\$	4,445	\$	17,994	\$	(5,720)	\$	29,534
Add back:														
Depreciation and amortization		15,651		4,261		3,959		3,836		8,220		7,380		16,491
Interest expense		6,206		1,641		1,013		1,439		2,654		2,929		5,931
Provision (benefit) for income taxes		3,553		2,941		4,229		1,517		7,170		(4,495)		15,218
EBITDA	\$	31,230	\$	15,845	\$	20,193	\$	11,237	\$	36,038	\$	94	\$	67,174
Add back:														
Restructuring and transaction costs <sup>(1)</sup>		5,335		_		693		2,203		693		2,802		3,246
Other general income <sup>(2)</sup>		(159)		_		_		_		_		_		(159)
Other expense, net <sup>(3)</sup>		1,137		(364)		(346)		756		(710)		961		(534)
Stock-based compensation expense <sup>(4)</sup>		32,239		2,747		2,105		2,818		4,852		26,541		10,550
Stock-based compensation payroll tax expense <sup>(5)</sup>		305		220		_		7		220		305		220
LTIP bonus <sup>(6)</sup>		1,369		144		160		174		304		558		1,115
Amortization of inventory step-up <sup>(7)</sup>		4,255		_		_		1,191				1,344		2,911
Adjusted EBITDA	\$	75,731	\$	18,592	\$	22,805	\$	18,386	\$	41,397	\$	32,605	\$	84,523
Adjusted EBITDA margin <sup>(9)</sup>		16.5%		16.6%		18.8%		15.6%		17.8 %		14.6 %		

- 1. Reflects the "Restructuring and transaction costs" line item on our consolidated statement of operations, which primarily includes transaction costs composed of legal and consulting fees, and \$1.0 million paid to Kanders & Company, Inc., a company controlled by our Chief Executive Officer, for services related to the acquisition of Cyalume, which is included in related party expense in the Company's consolidated statements of operations for the three and six months ended June 30, 2022.
- 2. Reflects the "Other general income" line item on our consolidated statement of operations and includes a gain from a long-lived asset sale.
- 3. Reflects the "Other (income) expense, net" line item on our consolidated statement of operations and primarily includes gains and losses on foreign currency transactions.
- 4. Reflects compensation expense related to equity and liability classified stock-based compensation plans.
- 5. Reflects payroll taxes associated with vested stock-based compensation awards.
- 6. Reflects the cost of a cash-based long-term incentive plan awarded to employees that vests over three years.
- 7. Reflects amortization expense related to the step-up inventory adjustment recorded as a result of our recent acquisitions.
- 8. Reflects Adjusted EBITDA / Net Sales for the relevant periods.

